Dzień Hematologii 2022, CAR-T w terapii nowotworów hematologicznych, NEXT_LEVEL, 15.11.2022
- Details
Szanowni Państwo,
Uprzejmie zapraszamy do udziału w wydarzeniu poświęconemu tematyce CAR-T w terapii nowotworów hematologicznych.
Spotkanie odbędzie się 15 listopada br. w Instytucie Genetyki Człowieka PAN w Poznaniu w ramach drugiego Dnia Hematologii, organizowanego w ramach europejskiego projektu NEXT_LEVEL.
Wydarzenie skierowane jest do różnych grup odbiorców m.in. uczniów szkół podstawowych i średnich, nauczycieli, pacjentów, studentów, naukowców i lekarzy specjalistów.
Jego celem jest przybliżenie szerokiej publiczności terapii CAR-T - obecnie najbardziej zaawansowanej i najbardziej nowoczesnej technologicznie formy immunoterapii komórkowej, która może być stosowana w leczeniu nowotworów takich jak chłoniaki i białaczki.
Wśród zaproszony prelegentów jest dwójka wybitnych polskich hemato – onkologów: prof. dr hab. n. med. Lidia Gil z Uniwersytetu Medycznego im. Karola Marcinkowskiego w Poznaniu oraz prof. dr hab. n. med. Grzegorz Basak z Uniwersyteckiego Centrum Klinicznego Warszawskiego Uniwersytetu Medycznego.
Szczegółowy program:
9:00 – 10:00 |
CAR-T - tajna broń w walce z nowotworami mgr Marta Kasprzyk, Instytut Genetyki Człowieka PAN |
10:30 – 11:30 |
CAR-T 2022 prof. dr hab. n. med. Lidia Gil, Uniwersytet Medyczny im. Karola Marcinkowskiego w Poznaniu |
12:00 – 13:00 |
Implementation of the CAR technology into clinics, product development and possible modifications - a scientist's perspective dr n. med. Tomasz Kolanowski, Instytut Genetyki Człowieka PAN |
13:30 – 14:30 |
CAR-T - and what's next? prof. dr hab. n. med. Grzegorz Basak, Uniwersyteckie Centrum Kliniczne Warszawskiego Uniwersytetu Medycznego |
Udział wydarzeniu jest bezpłatny. Każdy zainteresowany może zgłosić chęć uczestnictwa na miejscu w Instytucie Genetyki Człowieka PAN w Poznaniu lub online. Rejestracja dostępna jest na stronie: https://www.nextlevel-h2020.eu/hd2022/.
Dzień Hematologii 2022 jest organizowany w ramach projektu pt. „On the road to excellence in unravelling the (epi)genetic landscape of hematologic neoplasms” – NEXT_LEVEL finansowanego ze środków programu Unii Europejskiej w zakresie badań naukowych i innowacji – Horyzont 2020 w ramach umowy grantowej nr 952304. | |
Posiedzenie KGCiPM PAN, 8.12.2021
- Details
Plenarne posiedzenie Komitetu odbyło się w dniu 8 grudnia 2021 r. w formie on-line. Posiedzeniu przewodniczył prof. dr hab. Michał Witt.
Przedstawiono następujące doniesienia:
prof. Michał Witt z Instytutu Genetyki Człowieka PAN „Problem testów genetycznych w Polsce” pobierz
Prof. Jakub Pawlikowski z Uniwersytetu Medycznego w Lublinie „Prawa dawców materiału biologicznego w badaniach naukowych” pobierz
Dr Małgorzata Madej z Uniwersytetu Wrocławskiego „Regulacje prawne testów genetycznych w prawodawstwie europejskim” pobierz
Posiedzenie KGCiPM PAN, 28.01.2021
- Details
Plenarne posiedzenie Komitetu odbyło się w dniu 28 stycznia 2021 r. w formie on-line. Posiedzeniu przewodniczył prof. dr hab. Michał Witt.
Przedstawiono następujące doniesienia:
Prof. Jacek Wysocki z Uniwersytetu Medycznego im. Karola Marcinkowskiego w Poznaniu „Sytuacja epidemiologiczna w zakresie COVID-19”.
Prof. Janusz Limon, czł. rzecz. PAN „Albert de la Chapelle - wybitny genetyk i przyjaciel Polski”.
Dr Ewelina Kałużna z Instytutu Genetyki Człowieka PAN "Nagroda Nobla z medycyny i fizjologii 2020 dla odkrywców wirusa zapalenia wątroby C. Harvey J. Alter, Michael Houghton i Charles M. Rice."
Statement no. 6 of the Committee on the optimism of media reports on the national COVID-19 research of January 16, 2022
- Details
Statement no. 6 of the Committee on Human Genetics and Molecular Pathology of the Polish Academy of Sciences on the groundless optimism of media reports on the national COVID-19 research of January 16, 2022
During a pandemic, we are recipients of media reports that appear from time to time about the achievements of Polish entities, which are to significantly improve the bad epidemic situation. This is often combined with enthusiastic opinions of government representatives. This was the case with the Polish drug from the serum of convalescents, the Polish vaccine for COVID-19, and the Polish test for SARS-CoV-2. In all cases, the achieved effect, if any at all, does not correspond to the uncritical promises and optimistic statements publicized in the media.
In recent days, we hear a lot about the discovery of a gene mutation determining an increased predisposition to the severe clinical course of COVID-19, slightly more common in the Polish study group than in some other European countries. The transfer of information on this subject is accompanied by a media hustle and bustle, disproportionate to the merits of the case, combined with the lofty statements of the authorities of the Ministry of Health. There is no tangible scientific evidence to support these emphatic assurances. Without questioning the scientific value of the unknown research results, the Committee is strongly critical of this method of communicating the results of research work. It is a rule accepted in the world that the credibility of media enunciations must be based on appropriate scientific publications which have undergone an appropriate expert review procedure before the public announcement of the research results. Such publications should be available for viewing in a scientific journal as soon as they are publicized in the media. Obviously, the higher the journal's ranking, the higher the potential value of its results. The reference to a publication that is to appear in an undefined journal at an indefinite period of time bears the hallmarks of a lack of scientific professionalism.
Residual information, appearing in the flood of enthusiastic media reports, suggest an increased by several percent frequency of mutation (what?) Of the gene (what?) Present in chromosome 3, which causes a two-fold increase in the severity of the disease on COVID-19 in the group of patients studied in Poland. We do not know how it actually is, as we do not know the publication data so far, but for geneticists and pathologists the plans for immediate implementation of a genetic test that will detect this change sound amazing. The authors of the project are clearly unaware of the immensity of damage caused as a result of the uncritical acceptance of the results of commonly offered predisposition tests (and this is what we are talking about in this case), e.g. in oncology, where the obtained negative results reassure the respondents of a false and unjustified sense of health safety. In tests of this type, we deal only with a game of numerical, theoretical probabilities that have nothing to do with real individual clinical situations. The statement that such a test could be performed in HEDs sounds naive and contradicts scientific reason - what might be the sense of determining statistical genetic predisposition in acute medical scenarios that are dealt with by emergency departments of infectious hospitals?
The Committee on Human Genetics and Molecular Pathology of the Polish Academy of Sciences calls for the public not to be misled by the overly optimistic tone of such reports.
For the Committee on Human Genetics
and Molecular Pathology of the Polish Academy of Sciences
Chairman
/ - / prof. dr hab. med. Michał Witt
The above statement is fully endorsed by the Main Board of the Polish Society of Human Genetics.
Initiative "Vaccination against COVID-19. Innovative technologies and efficiency"
- Details
In December 2020, on the initiative of "Science against the pandemic", a study was created that provides information on vaccination, the technologies used and the need to fight the pandemic.
White Paper “Vaccinations against COVID-19. Innovative Technologies and Efficiency ”illustrates the medical rationales for vaccination, the examples of viral pandemics in history and the successful use of vaccines, justifies the use of vaccines to combat viral diseases. It indicates the scale of the current SARS-CoV-2 virus pandemic and the lack of available preventive measures and the importance of mass vaccination. In the following chapters the use of mRNA-based technology for the rapid development of new generation vaccines was discussed. Explains how the immune system works and the types of vaccines used. The following chapters discuss the available knowledge about the SARS-CoV2 virus, the importance of new vaccines and methods of obtaining and evaluating them, as well as discussing the vaccination plan and the importance of extensive vaccination.
Summarizing, it is a very valuable study of very current importance.
The Committee on Human Genetics and Molecular Pathology of the Polish Academy of Sciences fully supports this initiative and invites you to read the white paper "Vaccination against COVID-19. Innovative technologies and efficiency ”.
More information is available at https://naukaprzeciwpandemii.pl/en/
Download Vaccination against COVID-19. Innovative technologies and efficiency
- Inicjatywa "Szczepienia przeciw COVID-19. Innowacyjne technologie i efektywność"
- Szczepienia przeciw COVID-19, 2020
- Committee on Human Genetics and Molecular Pathology
- Statement of the Committee of Human Genetics and Molecular Pathology of the Polish Academy of Sciences on genetic tests for the presence of SARS-CoV-2 of June 12, 2020
Page 2 of 3